alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with clozapine in 6 studies
| Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 90 | 1 | 2 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernstein, E; Dextraze, P; Eison, MS; Lobeck, WG; New, JS; Taylor, DP; Temple, DL; Yevich, JP; Yocca, FD | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Harro, J; Lang, A; Soosaar, A; Vasar, E | 1 |
| Ciancone, MT; Haracz, JL; Rebec, GV; White, IM | 1 |
| Cler, JA; Iyengar, S; Oei, EJ; Rao, TS; Wood, PL | 1 |
| Wachtel, SR; White, FJ | 1 |
6 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and clozapine
| Article | Year |
|---|---|
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Molecular Structure; Piperazines; Pyrimidines; Rats; Receptors, Dopamine D2; Stereoisomerism; Stereotyped Behavior | 1992 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
The involvement of sigma and phencyclidine receptors in the action of antipsychotic drugs.
Topics: Animals; Brain; Clozapine; Ligands; Male; Mice; Motor Activity; Phencyclidine; Psychotropic Drugs; Pyrimidines; Rats; Receptors, Dopamine; Receptors, Opioid; Receptors, Phencyclidine; Receptors, sigma | 1992 |
A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Clozapine; Dextroamphetamine; Dose-Response Relationship, Drug; Haloperidol; Male; Psychotropic Drugs; Pyrimidines; Rats; Rats, Inbred Strains; Stereotyped Behavior; Sulpiride | 1992 |
Increased release of dopamine in vivo by BMY-14802: contrasting pattern to clozapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Anti-Anxiety Agents; Brain Chemistry; Clozapine; Corpus Striatum; Dibenzazepines; Dopamine; Homovanillic Acid; Male; Methyltyrosines; Mice; Olfactory Bulb; Pyrimidines | 1990 |
Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
Topics: Animals; Antipsychotic Agents; Apomorphine; Brain; Clozapine; Dopamine; Electrophysiology; Haloperidol; Male; Neurons; Pyrimidines; Rats; Rats, Inbred Strains | 1988 |